14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABCL vs GEGGL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Great Elm Group, Inc. 7.25% Notes due 2027 (GEGGL) captures the overall head-to-head institutional edge over AbCellera Biologics Inc. Common Shares (ABCL) on higher Unified Composite conviction (51.0/100 HOLD vs. 57.1/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ABCL wins 3–2 across the 6-pillar growth and valuation breakdown. ABCL trades at $9.69 (27.6x Forward P/E, -298.0% operating margin) versus GEGGL at $24.75 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. GEGGL 51.0/100 HOLD), GEGGL captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (+0.0% vs. +18.8% YoY).
Technical & Structure Timing Caution: ABCL is currently in a Breakdown options structure phase (RSI 33.8); meanwhile GEGGL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs GEGGL. Trailing 12-month operating profitability (ABCL -298.0% vs GEGGL 0.0%) and valuation multiples (ABCL 27.6x vs GEGGL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Services-Prepackaged Software value chain with N/A market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABCL vs GEGGL Key Questions & Quantitative Answers
As of Nov 20, 2026, Great Elm Group, Inc. 7.25% Notes due 2027 (GEGGL) captures the overall head-to-head institutional edge over AbCellera Biologics Inc. Common Shares (ABCL) on higher Unified Composite conviction (51.0/100 HOLD vs. 57.1/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ABCL wins 3–2 across the 6-pillar growth and valuation breakdown. ABCL trades at $9.69 (27.6x Forward P/E, -298.0% operating margin) versus GEGGL at $24.75 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. GEGGL 51.0/100 HOLD), GEGGL captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (+0.0% vs. +18.8% YoY). Technical & Structure Timing Caution: ABCL is currently in a Breakdown options structure phase (RSI 33.8); meanwhile GEGGL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABCL leads the Growth & Scale pillar: ABCL posts +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin), compared with GEGGL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABCL generates $68M in USD-normalized revenue versus N/A for GEGGL. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GEGGL.
ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 50.0x EV/Revenue (-48.4% FCF margin), whereas GEGGL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-14.6% ROE) versus GEGGL (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ABCL carries 86.5% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 85% Vol realized risk). By comparison, GEGGL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.02β · 9% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.